Arbekacin

Jump to navigation Jump to search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Arbekacin

Articles

Most recent articles on Arbekacin

Most cited articles on Arbekacin

Review articles on Arbekacin

Articles on Arbekacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Arbekacin

Images of Arbekacin

Photos of Arbekacin

Podcasts & MP3s on Arbekacin

Videos on Arbekacin

Evidence Based Medicine

Cochrane Collaboration on Arbekacin

Bandolier on Arbekacin

TRIP on Arbekacin

Clinical Trials

Ongoing Trials on Arbekacin at Clinical Trials.gov

Trial results on Arbekacin

Clinical Trials on Arbekacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Arbekacin

NICE Guidance on Arbekacin

NHS PRODIGY Guidance

FDA on Arbekacin

CDC on Arbekacin

Books

Books on Arbekacin

News

Arbekacin in the news

Be alerted to news on Arbekacin

News trends on Arbekacin

Commentary

Blogs on Arbekacin

Definitions

Definitions of Arbekacin

Patient Resources / Community

Patient resources on Arbekacin

Discussion groups on Arbekacin

Patient Handouts on Arbekacin

Directions to Hospitals Treating Arbekacin

Risk calculators and risk factors for Arbekacin

Healthcare Provider Resources

Symptoms of Arbekacin

Causes & Risk Factors for Arbekacin

Diagnostic studies for Arbekacin

Treatment of Arbekacin

Continuing Medical Education (CME)

CME Programs on Arbekacin

International

Arbekacin en Espanol

Arbekacin en Francais

Business

Arbekacin in the Marketplace

Patents on Arbekacin

Experimental / Informatics

List of terms related to Arbekacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA).[1][2] Arbekacin was originally synthesized from dibekacin in 1973. It has been registered and marketed in Japan since 1990 under the trade name Habekacin.[3] Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.

Pharmacology

Arbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

Pharmacodynamics

Aminoglycosides, such as Arbekacin, work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA which consequently, leaves the bacterium unable to synthesize proteins vital to its growth. Energy is needed for aminoglycoside uptake into the bacterial cell. Anaerobes have less energy available for this uptake, so aminoglycosides are less active against anaerobes. Aminoglycosides are useful primarily in infections involving aerobic, gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter.

Mechanism of action

Aminoglycosides, such as 'Arbekacin, inhibit protein synthesis in susceptible bacteria by irreversibly binding to bacterial 30S and 16S ribosomal subunits. Specifically Arbekacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

Absorption

Aminoglycosides are not well absorbed from the gastrointestinal tract. Their absorption is markedly improved by parenteral administration.

Toxicity

Ototoxicity and nephrotoxicity are the most serious adverse effects of aminoglycoside therapy and are more likely to occur in patients with a history of renal impairment or who are receiving other ototoxic and/or nephrotoxic drugs. Normal duration of IM or IV aminoglycoside therapy is 7–10 days. Although a longer duration may be necessary in some cases, toxicity is more likely to occur when aminoglycoside treatment is continued for longer than 10 days.

Affected organisms

Enteric bacteria and other eubacteria

References

  1. Inoue, M., M. Nonoyama, R. Okamoto, T. Ida (1994). "Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicilin-resistant Staphylococcus aureus". Drugs Exp Clin Res. 20 (6): 233–240. PMID 7758395.
  2. Cordeiro, J. C. R., Reis, A. O., Miranda, E. A., Sader, H. S., The Arbekacin Study Group (2001). "In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals". Brazilian J Infectious Diseases. 5 (3): 130–135. PMID 11506776.
  3. Kobayashi, Y., Uchida, H., Kawakami, Y. (1995). "Arbekacin". Intl J Antimicrobial Agents. 5 (4): 227–230. doi:10.1016/0924-8579(95)00014-Y. PMID 18611673.

Template:AminoglycosideAntiBiotics